Literature DB >> 3144429

Clostridium difficile: its disease and toxins.

D M Lyerly1, H C Krivan, T D Wilkins.   

Abstract

Clostridium difficile is the etiologic agent of pseudomembranous colitis, a severe, sometimes fatal disease that occurs in adults undergoing antimicrobial therapy. The disease, ironically, has been most effectively treated with antibiotics, although some of the newer methods of treatment such as the replacement of the bowel flora may prove more beneficial for patients who continue to relapse with pseudomembranous colitis. The organism produces two potent exotoxins designated toxin A and toxin B. Toxin A is an enterotoxin believed to be responsible for the diarrhea and mucosal tissue damage which occur during the disease. Toxin B is an extremely potent cytotoxin, but its role in the disease has not been as well studied. There appears to be a cascade of events which result in the expression of the activity of these toxins, and these events, ranging from the recognition of a trisaccharide receptor by toxin A to the synergistic action of the toxins and their possible dissemination in the body, are discussed in this review. The advantages and disadvantages of the various assays, including tissue culture assay, enzyme immunoassay, and latex agglutination, currently used in the clinical diagnosis of the disease also are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3144429      PMCID: PMC358025          DOI: 10.1128/CMR.1.1.1

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  223 in total

1.  Acute colitis related to penicillin and penicillin derivatives.

Authors:  R B Toffler; E G Pingoud; M I Burrell
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

2.  Biological activities of toxins A and B of Clostridium difficile.

Authors:  D M Lyerly; D E Lockwood; S H Richardson; T D Wilkins
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

3.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

4.  Simple method for isolation and presumptive identification of Clostridium difficile.

Authors:  I J Al-Jumaili; A J Bint
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1981

5.  Colitis induced by Clostridium difficile.

Authors:  J G Bartlett; T Chang; N S Taylor; A B Onderdonk
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

6.  Comparison of methods for recovery of Clostridium difficile from an environmental surface.

Authors:  B P Buggy; K H Wilson; R Fekety
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

7.  Detection of Clostridium difficile in faeces by direct gas liquid chromatography.

Authors:  P N Levett
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

8.  Toxin-producing bacteria in infants. Lack of an association with sudden infant death syndrome.

Authors:  M J Gurwith; C Langston; D M Citron
Journal:  Am J Dis Child       Date:  1981-12

9.  Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis.

Authors:  T A Bowden; A R Mansberger; L E Lykins
Journal:  Am Surg       Date:  1981-04       Impact factor: 0.688

10.  ADP-ribosylation in cultured cells treated with Clostridium difficile toxin B.

Authors:  I Florin; M Thelestam
Journal:  Biochem Biophys Res Commun       Date:  1986-08-29       Impact factor: 3.575

View more
  181 in total

1.  In vitro activity of linezolid against Clostridium difficile.

Authors:  T Peláez; R Alonso; C Pérez; L Alcalá; O Cuevas; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 2.  Passive immunity against human pathogens using bovine antibodies.

Authors:  C Weiner; Q Pan; M Hurtig; T Borén; E Bostwick; L Hammarström
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

3.  Toxin production by Campylobacter spp.

Authors:  T M Wassenaar
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Authors:  T Eric Ballard; Xia Wang; Igor Olekhnovich; Taylor Koerner; Craig Seymour; Joseph Salamoun; Michelle Warthan; Paul S Hoffman; Timothy L Macdonald
Journal:  ChemMedChem       Date:  2010-12-29       Impact factor: 3.466

5.  Purification and characterization of a UDP-glucosyltransferase produced by Legionella pneumophila.

Authors:  Iouri Belyi; Michel R Popoff; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A.

Authors:  S M Frey; T D Wilkins
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

7.  Monoclonal antibodies specific for Clostridium difficile toxin B and their use in immunoassays.

Authors:  F Müller; C Stiegler; U Hadding
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

8.  Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.

Authors:  M C Barc; C Depitre; G Corthier; A Collignon; W J Su; P Bourlioux
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Evaluation of an enzyme immunoassay for detection of Clostridium difficile toxin A.

Authors:  K Tsimidis; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-06       Impact factor: 3.267

10.  Impaired detection of faecal verocytotoxin in the presence of Clostridium difficile cytotoxin in patients with haemolytic uraemic syndrome.

Authors:  I Luzzi; F Minelli; A Gianviti; A Caprioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.